BACKGROUND: Perioperative window trials provide an opportunity to obtain intact tumor samples at two different time-points for evaluation of potential surrogate biomarkers. We report results of a pilot trial designed to determine if treatment-mediated changes in gene expression can be detected in formalin-fixed paraffin-embedded (FFPE) samples after 10-d exposure to anastrozole in estrogen receptor (ER)-positive breast cancer compared with untreated controls. METHODS: Paired tumor samples (biopsy, surgical) were obtained from 26 postmenopausal women with ER-positive breast cancer. Patients were assigned anastrozole (1 mg/d) for 10 d immediately prior to surgery (13 cases) or no treatment (13 controls). Five hundred two cancer-related genes were examined by the Illumina cDNA-mediated annealing, selection, extension, and ligation, FFPE cDNA array (moderated t-test, P ≤ 0.005). Surrogate biomarkers reflecting changes in gene expression were examined by immunohistochemistry (Wilcoxon rank-based test, P < 0.05). RESULTS: Sufficient RNA was available from 19 paired samples (8 controls, 11 cases). Frozen tissue and FFPE showed good correlation (r = 0.82). Within each group, 18 genes, reflecting roles in proliferation, angiogenesis, and apoptosis, showed differential expression from biopsy to surgery (P < 0.005). Estrogen-related genes were dysregulated in the treated group only. A reduction in Ki-67 was observed in 7 (54%) treated cases and in 1 (7.7%) control patient. CONCLUSIONS: 10-d exposure to anastrozole resulted in dysregulation of 18/502 cancer-related genes, and Ki-67 was reduced in 54% of cases. FFPE samples demonstrated good correlation with frozen samples. However, changes in gene expression and increased Ki-67 in the control group suggest local effects of wound healing may represent a confounding factor in the interpretation of perioperative window trials.
BACKGROUND: Perioperative window trials provide an opportunity to obtain intact tumor samples at two different time-points for evaluation of potential surrogate biomarkers. We report results of a pilot trial designed to determine if treatment-mediated changes in gene expression can be detected in formalin-fixed paraffin-embedded (FFPE) samples after 10-d exposure to anastrozole in estrogen receptor (ER)-positive breast cancer compared with untreated controls. METHODS: Paired tumor samples (biopsy, surgical) were obtained from 26 postmenopausal women with ER-positive breast cancer. Patients were assigned anastrozole (1 mg/d) for 10 d immediately prior to surgery (13 cases) or no treatment (13 controls). Five hundred two cancer-related genes were examined by the Illumina cDNA-mediated annealing, selection, extension, and ligation, FFPE cDNA array (moderated t-test, P ≤ 0.005). Surrogate biomarkers reflecting changes in gene expression were examined by immunohistochemistry (Wilcoxon rank-based test, P < 0.05). RESULTS: Sufficient RNA was available from 19 paired samples (8 controls, 11 cases). Frozen tissue and FFPE showed good correlation (r = 0.82). Within each group, 18 genes, reflecting roles in proliferation, angiogenesis, and apoptosis, showed differential expression from biopsy to surgery (P < 0.005). Estrogen-related genes were dysregulated in the treated group only. A reduction in Ki-67 was observed in 7 (54%) treated cases and in 1 (7.7%) control patient. CONCLUSIONS: 10-d exposure to anastrozole resulted in dysregulation of 18/502 cancer-related genes, and Ki-67 was reduced in 54% of cases. FFPE samples demonstrated good correlation with frozen samples. However, changes in gene expression and increased Ki-67 in the control group suggest local effects of wound healing may represent a confounding factor in the interpretation of perioperative window trials.
Authors: Jenny C Chang; Andreas Makris; M Carolina Gutierrez; Susan G Hilsenbeck; James R Hackett; Jennie Jeong; Mei-Lan Liu; Joffre Baker; Kim Clark-Langone; Frederick L Baehner; Krsytal Sexton; Syed Mohsin; Tara Gray; Laura Alvarez; Gary C Chamness; C Kent Osborne; Steven Shak Journal: Breast Cancer Res Treat Date: 2007-04-28 Impact factor: 4.872
Authors: Mitch Dowsett; Steve R Ebbs; J Michael Dixon; Anthony Skene; Clive Griffith; Irene Boeddinghaus; Janine Salter; Simone Detre; Margaret Hills; Susan Ashley; Stephen Francis; Geraldine Walsh; Ian E Smith Journal: J Clin Oncol Date: 2005-03-14 Impact factor: 44.544
Authors: Maurizia Mello-Grand; Vijay Singh; Chiara Ghimenti; Maria Scatolini; Lea Regolo; Enrico Grosso; Alberto Zambelli; Gian Antonio Da Prada; Laura Villani; Vittorio Fregoni; Paola Baiardi; Silvia Marsoni; William R Miller; Alberto Costa; Giovanna Chiorino Journal: Breast Cancer Res Treat Date: 2010-04-29 Impact factor: 4.872
Authors: K J Schmitz; R Callies; J Wohlschlaeger; R Kimmig; F Otterbach; J Bohr; H-S Lee; A Takeda; K W Schmid; H A Baba Journal: J Clin Pathol Date: 2006-02-23 Impact factor: 3.411
Authors: Alan Mackay; Ander Urruticoechea; J Michael Dixon; Tim Dexter; Kerry Fenwick; Alan Ashworth; Suzanne Drury; Alexey Larionov; Oliver Young; Sharon White; William R Miller; Dean B Evans; Mitch Dowsett Journal: Breast Cancer Res Date: 2007 Impact factor: 6.466
Authors: Javier I J Orozco; Shu-Ching Chang; Diego M Marzese; Janie G Grumley; Chikako Matsuba; Miquel Ensenyat-Mendez; Gary L Grunkemeier Journal: Ann Surg Oncol Date: 2021-07-09 Impact factor: 5.344
Authors: S Gandini; A Guerrieri-Gonzaga; G Pruneri; D Serrano; M Cazzaniga; M Lazzeroni; P Veronesi; H Johansson; B Bonanni; G Viale; A DeCensi Journal: Ann Oncol Date: 2013-12-18 Impact factor: 32.976
Authors: Dominic A Pearce; Laura M Arthur; Arran K Turnbull; Lorna Renshaw; Vicky S Sabine; Jeremy S Thomas; John M S Bartlett; J Michael Dixon; Andrew H Sims Journal: Sci Rep Date: 2016-07-07 Impact factor: 4.379
Authors: Sirwan M Hadad; Lee B Jordan; Pankaj G Roy; Colin A Purdie; Takayuki Iwamoto; Lajos Pusztai; Stacy L Moulder-Thompson; Alastair M Thompson Journal: BMC Cancer Date: 2016-09-22 Impact factor: 4.430